When is Alzheimer's not dementia-Cochrane commentary on The National Institute on Ageing and Alzheimer's Association Research Framework for Alzheimer's Disease.


Journal

Age and ageing
ISSN: 1468-2834
Titre abrégé: Age Ageing
Pays: England
ID NLM: 0375655

Informations de publication

Date de publication:
01 03 2019
Historique:
received: 01 09 2018
accepted: 21 09 2018
pubmed: 18 10 2018
medline: 21 3 2020
entrez: 18 10 2018
Statut: ppublish

Résumé

Early 2018 saw the release of new diagnostic guidance on Alzheimer's disease from the National Institute on Ageing and the Alzheimer's Association (NIA-AA). This proposed research framework represents a fundamental change in how we think about Alzheimer's disease, moving from diagnosis based on clinical features to diagnosis based solely on biomarkers. These recommendations are contentious and have important implications for patients, clinicians, policy makers and the pharmaceutical industry. In this commentary, we offer a summary of the NIA-AA research framework. We then focus on five key areas: divorcing neuropathology from the clinical syndrome; the emphasis placed on one dementia subtype; validity of available biomarkers; the changing meaning of the term 'Alzheimer's disease'; and the potential for a research framework to influence clinical practice.

Identifiants

pubmed: 30329009
pii: 5133577
doi: 10.1093/ageing/afy167
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

174-177

Subventions

Organisme : Chief Scientist Office [UK]
Pays : International

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Jenny McCleery (J)

Cochrane Dementia and Cognitive Improvement Group, University of Oxford, UK.

Leon Flicker (L)

Cochrane Dementia and Cognitive Improvement Group, University of Oxford, UK.
Western Australia Centre for Health & Ageing, University of Western Australia, Perth, Australia.

Edo Richard (E)

Cochrane Dementia and Cognitive Improvement Group, University of Oxford, UK.
Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, Netherlands.

Terence J Quinn (TJ)

Cochrane Dementia and Cognitive Improvement Group, University of Oxford, UK.
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH